Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
55 hedge funds and large institutions have $84.2M invested in Cidara Therapeutics in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
189% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 9
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
20% more funds holding
Funds holding: 46 → 55 (+9)
25% less capital invested
Capital invested by funds: $112M → $84.2M (-$28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.84M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$968K |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$726K |
| 4 |
PA
Perceptive Advisors
New York
|
+$605K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$553K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.24M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.97M |
| 3 |
Goldman Sachs
New York
|
-$3.2M |
| 4 |
DM
Deerfield Management
New York
|
-$873K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$498K |
CDTX Hedge Fund Activity: Q2 2016 in Review
55 of the 3,755 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2016, worth a combined $84.2M — down 25% from $112M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CDTX positions and 4 closed out — a net gain of 9 holders — while 26 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $1.84M. The largest seller was RA Capital Management, cutting an estimated $9.24M.
- 55 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2016, up from 46 in Q1 2016.
- Funds reported $84.2M of Cidara Therapeutics stock for Q2 2016, down 25% quarter-over-quarter.
- 13 funds opened new Cidara Therapeutics positions in Q2 2016 and 4 closed out, a net change of +9 holders.
- The largest Cidara Therapeutics buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $1.84M added.
- The largest Cidara Therapeutics seller in Q2 2016 was RA Capital Management, an estimated $9.24M sold.
Based on aggregated 13F filings for Q2 2016.